Phytochemical investigation of the stems of Eurycoma longifolia Jack led to the isolation of two new canthin-6-one alkaloids, 4,9-dimethoxycanthin-6-one (1) and 10-hydroxy-11-methoxycanthin-6-one (2), and a new tirucallane-type triterpenoid, 23,24,25-trihydroxytirucall-7-en-3,6-dione (3), along with 37 known compounds. Among these, an oxasqualenoid (4) was isolated as a natural product for the first time. The structures of the isolates were elucidated by spectroscopic and mass spectrometric means. All the isolates were evaluated for their cytotoxic activity against a HT-1080 human fibrosarcoma cell line. Among them, 9,10-dimethoxycanthin-6-one (14, IC 50 = 5.0 μM), 10-hydroxy-9-methoxycanthin-6-one (15, IC 50 = 7.2 μM), dihydroniloticin (18, IC 50 = 8.2 μM), and 14-deacetyleurylene (34, IC 50 = 3.2 μM) displayed stronger activity than the positive control 5-FU (IC 50 = 9.2 μM).
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Eurycoma longifolia Jack (Simaroubaceae) is an indigenous shrub, widely distributed in the rain forests of Southeast Asia. It is widely used as an aphrodisiac tonic, as an anti-malarial drug, and as a health supplement [1a-1c] . The crude extracts of this plant were reported to increase sexual performances in experimental male rats [2a] [3] . In continuation, we recently isolated two new canthin-6-one alkaloids (1, 2) and a new tirucallane-type triterpenoid (3), together with 37 known compounds: an oxasqualenoid (4) [4a] , 1hydroxycanthin-6-one (5) [4b], 9-methoxycanthin-6-one (6) [4c], 9-methoxycanthin-6-one-3-oxide (7) [4c], 9hydroxycanthin-6-one (8) 13, 3.99) . These data, except for that of the singlet olefinic proton (δ H 6.17) ascribable to H-5, were similar to those of 5,9-dimethoxycanthin-6-one (12), isolated from the same extract. Thus, compound 1 was considered to be 4,9-dimethoxycanthin-6-one, which was supported by the NOE enhancement between 4-OCH 3 /H-5, 9-OCH 3 /H-8, and 9-OCH 3 /H-10 ( Figure 1 ). The molecular formula of compound 2 was determined to be C 15 H 10 N 2 O 3 by HRFABMS (m/z 267.0738). The 1 H NMR spectrum of 2 displayed signals of three pairs of ortho-coupled aromatic protons (δ H 8.82, 8.16; δ H 8.12, 6.98; δ H 8.06, 7.28) , methoxyl protons (δ H 4.07), and a hydroxyl proton (δ H 9.95). These signals were similar to those of 10-hydroxy-9-methoxycanthin-6-one (15), isolated from the same extract, but the 1 H-NMR spectrum of 2 showed the signals of a pair of ortho-coupled aromatic protons instead of those of two singlet protons (δ H 8.06, 7.01) in 15. The position of the methoxyl group was confirmed by the NOE difference experiment ( Figure  1 ) to be at C-11. Thus, compound 2 was concluded to be 10-hydroxy-11-methoxycanthin-6-one. , except for the signals of the side chain moiety. Hence, compound 3 was considered to have the same rings A-D as dyvariabilin A. On the other hand, the 1 H and 13 C NMR signals ascribable for the side chain moiety were comparable to those of piscidinol A (23), isolated from the same extract. Therefore, compound 3 was considered to have the same side chain moiety as 23. Thus, compound 3 was concluded to be 23,24,25trihydroxytirucall-7-en-3,6-dione, which was supported by the COSY and HMBC spectra ( Figure 2 ). The relative configuration of 3, except for the side chain moiety, was determined by the NOE difference experiment ( Figure 2 ).
Compound 4 was isolated as amorphous solid and its 1 H and 13 C NMR data were identical to those of a synthetic oxasqualenoid [4a] . However, this is the first isolation of this compound from a natural source.
All the isolated compounds, except for 9 and 31, were tested for their cytotoxic activity against the HT-1080 cell line [11a] (Table 1) . Clinically used anticancer agents, 5fluorouracil (5-FU) and doxorubicin (Dox) [11b], were used as positive controls in this study.
The tested compounds exhibited different potencies of activity in a concentration dependent manner and 14deacetyleurylene (34) showed the most potent activity with an IC 50 value of 3.2 µM. Among the canthine alkaloids (1−2, 5−15), 9,10-dimethoxycanthin-6-one (14, IC 50 = 5.0 µM) and 10-hydroxy-9-methoxycanthin-6-one (15, IC 50 = 7.2 µM) displayed the most potent cytotoxicity, while among the tirucallanoids (3, 17−30), dihydroniloticin (18) 
Cell line:
Highly metastatic HT-1080 human fibrosarcoma cell line (ATCC#CCL-121) was obtained from the American Type Culture Collection (Rockville, MD, USA), and was maintained in MEMα, which was supplemented with 10% FBS, 0.1% NaHCO 3 , and 1% antibiotic antimycotic solution.
Cytotoxic activity assay:
Cell viability in the presence or absence of tested compounds was determined by using the standard MTT assay [12] , as described previously [13] . In brief, exponentially growing cells were harvested and plated in 96-well plates (2 × 10 3 cells/well). After 24 h incubation at 37°C under a humidified 5% CO 2 atmosphere to allow cell attachment, the cells were treated with various concentrations of test specimens in medium (100 μL). After 72 h incubation, 100 μL of MTT solution (0.5 mg/mL) was added to the wells. After 2 h incubation, the formazan formed was extracted with DMSO and its amount was measured spectrophotometrically at 550 nm with a Perkin-Elmer HTS-7000 bioassay reader (Norwalk, CT, USA 
MeOH (2 L); collection volume 500 mL] to yield 40 fractions.
A part of fraction 18 (766 mg), eluted with 2% MeOH-CH 2 Cl 2 , was subjected to MPLC on silica gel (37 mm × 300 mm) with an EtOAc−n-hexane gradient system (0:1 → 3:7 → 1:1 → 4:1 → 1:0; each 1 L) to yield 16 subfractions. Subfraction 6 (17.1 mg) was applied to normal-phase preparative TLC using EtOAc-CH 2 Cl 2 (1:9) to yield 32 (1.2 mg). Compound 37 (5.3 mg) was isolated from subfraction 8 (44.0 mg). Subfraction 11 (30.8 mg) was purified by normal-phase preparative TLC with MeOH-CHCl 3 (1:24) and normal-phase preparative TLC with MeOH-benzene (1:24) to yield 10 (1.6 mg) and 38 (0.9 mg). Subfraction 13 (8.9 mg) was subjected to reversed-phase preparative TLC with MeOH to yield 23 (1.8 mg).
Fraction 19 (667 mg), eluted with 2% MeOH-CH 2 Cl 2 , was further subjected to MPLC on silica gel (37 mm × 300 mm) with an EtOAc-n-hexane gradient system (0:1 → 1:4 → 3:7 → 1:1 → 7:3 → 1:0; each 1 L) to yield 14 subfractions. Subfraction 3 (32.7 mg) was further purified by normal-phase preparative TLC with EtOAc-benzene (3:17) and reversed-phase preparative TLC with MeOH-CH 3 CN-H 2 O (2:2:1) to yield 35 (12.6 mg) . Subfraction 6 (142 mg) was applied to normal-phase preparative TLC with EtOAc-n-hexane (3:7), followed by normal-phase preparative TLC with EtOAc-CH 2 Cl 2 (1:9), to afford 17 (40.8 mg) and 27 (2.0 mg). Subfraction 7 (56.7 mg) was subjected to reversed-phase preparative TLC with MeOH-CH 3 CN-H 2 O (2:2:1) to yield 22 (9.6 mg). Subfraction 9 (28.0 mg) was purified with normal-phase preparative TLC with MeOH-benzene (1:19) and normal-phase preparative TLC with EtOAc-n-hexane (1:1) to afford 36 (0.9 mg). Subfraction 14 (29.5 mg) was applied to normal-phase preparative TLC with MeOH-benzene (1:9) to yield 13 (1.1 mg).
Fraction 20 (1.20 g), eluted with 2% MeOH-CH 2 Cl 2 , was subjected to MPLC on silica gel (37 mm × 300 mm) with an EtOAc-n-hexane gradient system [0:1 (1 L) → 2:3 (500 mL) → 4:1 (1 L) → 1:0 (500 mL)], followed by MeOH-EtOAc (1:9 → 1:4; each 500 mL), to yield 13 subfractions. Subfraction 3 (145 mg) was determined as 33 by comparison with published data. Subfraction 5 (265 mg) was further purified by MPLC on ODS silica gel (26 mm × 300 mm) with MeOH-CH 3 CN-H 2 O (2:2:1; 1 L), MPLC on ODS silica gel (26 mm × 300 mm) with CH 3 CN-H 2 O (4:1; 1 L), reversed-phase preparative TLC with MeOH-H 2 O (9:1), and normal-phase preparative TLC with acetone-CH 2 Cl 2 (1:9) to yield 28 (1.7 mg) and 29 (1.1 mg). Subfraction 8 (27.6 mg) was subjected to normal-phase preparative TLC with MeOH-benzene (1:19) to yield 6 (4.1 mg). Subfraction 11 (23.2 mg) was applied to normal-phase preparative TLC with MeOHbenzene (7:93) to afford 14 (3.9 mg). Subfraction 13 (38.0 mg) was further purified by normal-phase preparative TLC with acetone-n-hexane (3:7) and reversed-phase preparative TLC with MeOH-H 2 O (4:1) to yield 1 (2.1 mg) and 11 (1.3 mg).
Fraction 21 (540 mg), eluted with 4% MeOH-CH 2 Cl 2 , was subjected to MPLC on silica gel (37 mm × 300 mm) with a MeOH-CHCl 3 gradient system [0:1 (2 L) → 1:199 (2 L) → 1:99 (2 L) → 1:19 (1 L) → 3:7 (1 L)] to yield 10 subfractions. Subfraction 2 (54.5 mg) was applied to reversed-phase preparative TLC with MeOH-CH 3 CN-H 2 O (9:9:2), followed by normal-phase preparative TLC with acetone-CH 2 Cl 2 (3:17), to afford 18 (9.2 mg) and 21 (2.5 mg). Subfraction 3 (88.5 mg) was subjected to reversed-phase preparative TLC with MeOH-CH 3 CN-H 2 O (9:9:2) to yield 30 (5.7 mg). Combined subfractions 4 and 5 (157 mg) were successively subjected to MPLC on silica gel (11 mm × 300 mm) with an acetone-CH 2 Cl 2 gradient system (0:1 → 1:19 → 1:9 → 1:4, followed by 20% MeOH-CH 2 Cl 2 ; each 100 mL), reversed-phase preparative TLC with MeOH-CH 3 CN-H 2 O (2:2:1), and normal-phase preparative TLC with acetone-CH 2 Cl 2 (1:9) to yield 20 (13.5 mg) and 31 (0.5 mg). Subfraction 6 (209 mg) was further purified by MPLC on silica gel (11 mm × 300 mm) with an acetone-n-hexane gradient system (0:1 → 1:4 → 3:7 → 1:1; each 400 mL), reversed-phase preparative TLC with MeOH-CH 3 CN-H 2 O (2:2:1), and normal-phase preparative TLC with acetone-CH 2 Cl 2 (1:4) to yield 40 (0.9 mg).
Fractions 22 (670 mg) and 23 (1.10 g), eluted with 4% MeOH-CH 2 Cl 2 , were combined and subjected to MPLC on silica gel (37 mm × 300 mm) with an acetone-CH 2 Cl 2 gradient system (1:9 → 1:4 :1) , and normal-phase preparative TLC with EtOAc-CH 2 Cl 2 (3:2) to afford 4 (1.0 mg), 12 (0.7 mg), and 15 (0.7 mg).
A part (592 mg) of combined fractions 24 and 25 (4% and 8% MeOH-CH 2 Cl 2 eluate) was subjected to MPLC on silica gel (37 mm × 300 mm) with a MeOH-CHCl 3 gradient system (0:1 → 1:99 → 1:49 → 1:19 → 3:7; each 1 L) to yield 9 subfractions. Subfraction 4 (24.5 mg) was purified by reversed-phase preparative TLC with MeOH-CH 3 CN-H 2 O (2:2:1) and normal-phase preparative TLC with acetone-CH 2 Cl 2 (1:4) to yield 7 (1.2 mg) and 26 (3.8 mg) . From subfraction 5 (43.4 mg), 9 (0.5 mg) was isolated and 39 (0.7 mg) was yielded by purification of subfraction 7 (30.8 mg). Subfraction 8 (51.6 mg) was purified by reversed-phase preparative TLC with MeOH-CH 3 CN-H 2 O (1:1:2) to yield 5 (0.7 mg). Subfraction 9 (22.3 mg) was purified by reversed-phase preparative TLC with MeOH-CH 3 CN-H 2 O (1:1:2) and normal-phase preparative TLC with acetone-CH 2 Cl 2 (3:17) to afford 8 (1.4 mg).
Fraction 28 (548 mg), eluted with 8% MeOH-CH 2 Cl 2 , was subjected to MPLC on silica gel (37 mm × 300 mm) with a MeOH-benzene gradient system [1:9 (2 L) → 1:4 (1 L)] to yield 7 subfractions. Subfraction 2 (164 mg) was further purified by MPLC on ODS silica gel (26 mm × 300 mm) with a MeOH-H 2 O gradient system (0:1 → 3:7 → 1:1 → 7:3 → 1:0; each 500 mL) and normal-phase preparative TLC with EtOAc-n-hexane (4:1) to yield 16 (0.6 mg).
4,9-Dimethoxycanthin-6-one (1)
Yellow amorphous solid. UV λ max (EtOH) nm (log ε): 219 (4.10), 275 (4.09), 309 (3.86), 348 (3.85) . IR (CHCl 3 ): 1660, 1635, 1605, 1590, 1565, 1495, 1480, 1460, 1440, 1425, 1400, 1325, 1310, 1300, 1275, 1240, 1155, 1100, 1060 
Compound 4
Colorless amorphous solid.
[α] D 25 : +9 (c 0.09, CHCl 3 ). 1 H NMR (400 MHz, CDCl 3 ): 1.16 (3H, s), 1.26 (3H, s), 1.62 (3H, s), 1.68 (3H, s), 3.58 (1H, d, J = 9.8 Hz), 3.84 (1H, t, J = 7.3 Hz), 5.11 (1H, t, J = 6.5 Hz). 13 C NMR (100 MHz, CDCl 3 ): 17. 7, 22.3, 24.0, 24.2, 25.7, 26.6, 29.5, 31.7, 38.4, 74.1, 77.7, 84.1, 86.1, 124.4, 132. 
